Dr. John Cush RheumNow
2 years 3 months ago
JAK inhibitors have been used as adjunctive therapy to reduce flammation arising with checkpoint inhibitor use in cancer (Hodgkins, Lung CA), using itacitinib w/ pembrolizumab or ruxolitinib & nivolumab improved trial outcomes https://t.co/eF6wO72D80 https://t.co/IFDYuI71X5
Dr. John Cush RheumNow
2 years 3 months ago
EUSTAr study of 4431 systemic sclerosis (SSc) pts - anti-SSA antibodies are detected in 15% of SSc-patients and represent an independent risk factor for the presence of lung fibrosis (OR 1.24) & more severe lung involvement. #EULA2024 OP0013 https://t.co/NcxReWk83n https://t.co/FSMx22XiNo
Dr. John Cush RheumNow
2 years 3 months ago
Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT:
data now out to 60w
good humoral and cellular response in most, even without MTX withheld
(& good safety too)
Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020
Dr. John Cush RheumNow
2 years 3 months ago
Moonlake has announced its phase 3 program to develop Sonelokimab (M1095) a dual inhibitor of IL-17A & IL-17F for use in Psoriatic arthritis. IZAR-1 & IZAR-2 Ph 3 DBPCT will enroll 1,500 adults w/ active PsA, w/ ACR 50 endpoint at Week 16 https://t.co/y3UvOF4M5i https://t.co/iSUrkhIXbh
Dr. John Cush RheumNow
2 years 3 months ago
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/gvRzYpFl5i https://t.co/uSISWG3foy
Dr. John Cush RheumNow
2 years 3 months ago
The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria.
https://t.co/7hJeTf3O6y https://t.co/V43YHjhEhn
NatRevRheumatol NatRevRheumatol
2 years 3 months ago
#JulyIssue | This #Review provides an overview of the immunological, clinical and pathophysiological features of anti-citrullinated protein antibodies in #RheumatoidArthritis
Check it out here: https://t.co/dzMHF9ETyu https://t.co/hRzkLp6K9g
Dr. John Cush RheumNow
2 years 3 months ago
Prevention of Psoriatic Arthritis
Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria.
https://t.co/BHnTciKU1f https://t.co/P7gDZUSGRw
Dr. John Cush RheumNow
2 years 3 months ago
JAK Inhibitors in GCA
Trials are underway evaluating the potential benefits of JAKi in GCA patients who are refractory to standards of care. An observational real-world analysis of a small worldwide cohort suggests the utility of JAKi in GCA.
https://t.co/d4IsqBgkxQ https://t.co/PIDhwzgNym
Dr. John Cush RheumNow
2 years 3 months ago
Difficult-to-Treat Psoriasis
This meta-analysis of psoriasis treatments shows that biologic therapies may be less effective in certain psoriasis (PSO) patients, particularly those who are older, smokers, with higher BMI an prior exposure to biologics.
https://t.co/OWzmYShqBs https://t.co/u1995MAB15
Dr. John Cush RheumNow
2 years 3 months ago
Low Back Pain? Take a Walk!
A randomised controlled trial of adults with recurrent low back pain (LBP) has shown that a program of progressive walking and education intervention significantly reduced low back pain recurrence.
https://t.co/FTm69VviD1 https://t.co/q53EIxAc1J
Dr. John Cush RheumNow
2 years 3 months ago
RT: @synovialjoints In a Swedish-Danish cohort study on patients with PsA, treatment with TNFi was associated with a small increased risk of NMSC and with non-significant numeric risk increases for both BCC and SCC compared with bDMARD naïve #EULAR2024 Abstract 0150
Dr. John Cush RheumNow
2 years 3 months ago
RT: @aurelierheumo
TOLERA trial in RA
RTX/ABA sequence versus RTX alone
10pts each group
Primary outcome was ambitious: ACPA seroconversion
No difference between ttmts (and also no seroconversion)
No diff in disease activity
No diff in ACPA change wt wk52
OP0069 #EULAR2024
The New England Journal of Medicine has published a review of systemic amyloidosis. "Amyloidosis, a systemic disease that manifests in various ways, should be in the differential diagnosis of unexplained proteinuria, restrictive cardiomyopathy, peripheral and autonomic neuropathy, and hepatomegaly."
Dr. John Cush RheumNow
2 years 3 months ago
RT @yuz6yusof #EULAR2024 Cutaneous #lupus is variable & can be difficult to treat. Promising post-hoc data frm Phase 2 RCT showing Deucravacitinib (Tyk2-i) led to improvement & sustained CLASI-50 response in all subtypes (ACLE, SCLE, Chonic and Discoid) #EULARBEST
